Overview

Phase 1 Study of ATRS-2002 in Healthy Male Adults

Status:
Not yet recruiting

Trial end date:
2021-12-28

Target enrollment:

Participant gender:

Summary

To access the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ATRA-2002 against commercially available oral formulation of abiraterone acetate in healthy male adults

Phase:

Phase 1

Details

Lead Sponsor:

Syneos Health

Collaborator:

Antares Pharma Inc.

Treatments:

Abiraterone Acetate